4
MARKET OVERVIEW
Summarizes the competitive environment, macro signals, and segment-level movements driving market outcomes.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Maps the market evolution with focus on trend catalysts, risk factors, and growth opportunities across segments.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN MIDDLE EAST & AFRICA HEALTHCARE INDUSTRY
5.2.4
TRENDS IN MIDDLE EAST & AFRICA DRUG DELIVERY INDUSTRY
5.3
SUPPLY CHAIN ANALYSIS
5.6.1
AVERAGE SELLING PRICE TREND OF END-USE INDUSTRY, BY KEY PLAYER (2023–2025)
5.6.2
AVERAGE SELLING PRICE TREND, BY PRODUCT (2023–2025)
5.6.3
AVERAGE SELLING PRICE TREND, BY REGION (2023–2025)
5.7.1
IMPORT SCENARIO (HS CODE 9018)
5.7.2
EXPORT SCENARIO (HS CODE 9018)
5.8
KEY CONFERENCES AND EVENTS, 2026–2027
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10
INVESTMENT AND FUNDING SCENARIO
5.11
SUCCESS STORIES AND REAL-WORLD APPLICATIONS
5.12
IMPACT OF 2025 US TARIFF – MEA INJECTABLE DRUG DELIVERY MARKET
5.12.3
PRICE IMPACT ANALYSIS
5.12.4
IMPACT ON COUNTRIES
0.0.1
IMPACT ON HEALTHCARE PROVIDER SEGMENTS
0.0.1.1
HOSPITALS & CLINICS
0.0.1.2
HOME CARE SETTINGS
0.0.1.3
LONG-TERM CARE SETTINGS
NOTE: OTHER END USERS INCLUDE COSMETIC CLINICS, DIAGNOSTIC LABORATORIES, CLINICAL RESEARCH, ACADEMIC & RESEARCH INSTITUTIONS, AND HEALTHCARE PROVIDERS.
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
0.1
KEY EMERGING TECHNOLOGIES
6.1.2
MICRONEEDLE & NEEDLE-FREE INJECTION TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
TELEHEALTH & REMOTE MONITORING PLATFORMS
6.2.2
AI-ENABLED DEVICE DESIGN & PREDICTIVE DOSING TOOLS
6.3
ADJACENT TECHNOLOGIES
6.3.1
HIGH-VISCOSITY DELIVERY ENHANCEMENT SYSTEMS
6.3.2
ADVANCED PRIMARY PACKAGING FOR INJECTABLES
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.7
IMPACT OF AI/GEN AI ON MEA INJECTABLE DRUG DELIVERY MARKET
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
BEST PRACTICES IN MEA INJECTABLE DRUG DELIVERY MARKET
6.7.3
CASE STUDIES OF AI IMPLEMENTATION IN THE MEA INJECTABLE DRUG DELIVERY MARKET
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MEA INJECTABLE DRUG DELIVERY MARKET
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
SUSTAINABILITY INITIATIVES
7.2.1
ENERGY-EFFICIENT SYSTEM DESIGN AND USE OF RECYCLABLE MATERIALS IN INJETCABLE DRUG DELIVERY PRODUCTS
7.3
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.4
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
COMPARATIVE ASSESSMENT OF KEY INJECTABLE DRUG DELIVERY PRODUCTS, THEIR MARKET POTENTIAL, AND DEMAND PATTERNS BY VARIOUS MANUFACTURER COMPANIES
Market Size, Volume & Forecast – USD Million
9.2
VOLUME ANALYSIS OF INJECTABLE DRUG DELIVERY PRODUCTS, 2024 – 2031 (THOUSAND UNITS)
9.3.1
CONVENTIONAL INJECTION DEVICES
9.3.1.1.1
GLASS INJECTABLE DEVICES
9.3.1.1.2
PLASTIC INJECTABLE DEVICES
9.3.1.2.1
FILLABLE SYRINGES
9.3.1.2.2
PREFILLED SYRINGES
9.3.1.3.1
REUSABLE INJECTION DEVICES
9.3.1.3.2
DISPOSABLE INJECTION DEVICES
9.3.2
SELF-INJECTION DEVICES
9.3.2.1
NEEDLE-FREE INJECTORS
9.3.2.1.1.1
FILLABLE NEEDLE-FREE INJECTORS
9.3.2.1.1.2
PREFILLED NEEDLE-FREE INJECTORS
9.3.2.1.2.1
JET-BASED NEEDLE-FREE INJECTORS
9.3.2.1.2.2
SPRING-BASED NEEDLE-FREE INJECTORS
9.3.2.1.2.3
LASER-POWERED NEEDLE-FREE INJECTORS
9.3.2.1.2.4
VIBRATION-BASED NEEDLE-FREE INJECTORS
9.3.2.1.3.1
REUSABLE NEEDLE-FREE INJECTORS
9.3.2.1.3.2
DISPOSABLE NEEDLE-FREE INJECTORS
9.3.2.2.1.1
FILLABLE AUTOINJECTORS
9.3.2.2.1.2
PREFILLED AUTOINJECTORS
9.3.2.2.2.1
AUTOMATED AUTOINJECTORS
9.3.2.2.2.2
MANUAL AUTOINJECTORS
9.3.2.2.3.1
STANDARDIZED AUTOINJECTORS
9.3.2.2.3.2
CUSTOMIZED AUTOINJECTORS
9.3.2.2.4.1
REUSABLE AUTOINJECTORS
9.3.2.2.4.2
DISPOSABLE AUTOINJECTORS
9.3.2.3.1.1
SINGLE-CHAMBERED PEN INJECTORS
9.3.2.3.1.2
DOUBLE-CHAMBERED PEN INJECTORS
9.3.2.3.2.1
STANDARD PEN INJECTORS
9.3.2.3.2.2
CUSTOMIZED PEN INJECTORS
9.3.2.3.3.1
REUSABLE PEN INJECTORS
9.3.2.3.3.2
DISPOSABLE PEN INJECTORS
9.3.2.4
WEARABLE INJECTORS
9.3.2.5
OTHER SELF-INJECTION DEVICES
NOTE: OTHER INJECTABLE DEVICES INCLUDE BLUNT NEEDLES, MICRONEEDLES, AND NANONEEDLE INJECTIONS.
9.4.1
CONVENTIONAL DRUG DELIVERY FORMULATIONS
9.4.1.2
RECONSTITUTED/LYOPHILIZED FORMULATIONS
9.4.2
NOVEL DRUG DELIVERY FORMULATIONS
9.4.2.1
COLLOIDAL DISPERSIONS
9.4.2.1.3
POLYMERIC/MIXED MICELLES
9.4.2.1.4.1
SOLID-LIPID NANOPARTICLES
9.4.2.1.4.2
NANOSUSPENSIONS
9.4.2.1.4.3
NANOEMULSIONS
9.4.3
LONG-ACTING INJECTABLE FORMULATIONS
10
MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
FORMULATION PACKAGING-WISE DEMAND POTENTIAL AND GROWTH PATHWAYS SHAPING INJECTABLE DRUG DELIVERY ADOPTION IN DIVERSE INDUSTRIES
11
MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
THERAPEUTIC APPLICATION-WISE DEMAND POTENTIAL AND GROWTH PATHWAYS SHAPING INJECTABLE DRUG DELIVERY ADOPTION IN DIVERSE INDUSTRIES
11.2.1
RHEUMATOID ARTHRITIS
11.2.2
MULTIPLE SCLEROSIS
11.2.5
OTHER AUTOIMMUNE DISEASES
11.3.2
REPRODUCTIVE HEALTH DISEASES
11.3.3
ANTITHROMBOTIC/THROMBOLYTIC THERAPY
11.3.5
GROWTH HORMONE DEFICIENCY
11.8
OTHER THERAPEUTIC APPLICATIONS
11.8.3
AESTHETIC TREATMENTS
NOTE: OTHER AUTOIMMUNE HEPATITIS, ADDISON’S DISEASE, MYASTHENIA GRAVIS, PERNICIOUS ANEMIA, HASHIMOTO'S THYROIDITIS, CARDIOMYOPATHY, ANTIPHOSPHOLIPID SYNDROME, GUILLAIN-BARRÉ SYNDROME, SJÖGREN’S SYNDROME, AND ALOPECIA.
NOTE: OTHER THERAPEUTIC APPLICATIONS INCLUDE ALLERGIES, AESTHETIC TREATMENT, HEPATITIS C, AND HEMOPHILIA.
12
MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
USAGE PATTERN DEMAND PATTERNS AND GROWTH DRIVERS IMPACTING INJECTABLE DRUG DELIVERY ADOPTION
12.4
OTHER USAGE PATTERNS
NOTE: OTHER USAGE PATTERNS INCLUDE BLOOD TRANSFUSION, BLOOD PRODUCTS, AND CONTRACEPTIVES.
13
MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
SITE OF ADMINISTRATION-WISE DEMAND POTENTIAL AND GROWTH PATHWAYS SHAPING INJECTABLE DRUG DELIVERY ADOPTION IN DIVERSE INDUSTRIES
13.2
DERMAL-BASED ADMINISTRATION
13.3
CIRCULATORY/MUSCULOSKELETAL SYSTEM-BASED ADMINISTRATION
13.4
ORGAN-BASED ADMINISTRATION
13.5
CENTRAL NERVOUS SYSTEM-BASED ADMINISTRATION
14
MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
SECTOR-SPECIFIC ADOPTION DRIVERS, DEMAND DYNAMICS, AND MARKET POTENTIAL ACROSS EACH END-USE INDUSTRY
14.4
LONG-TERM CARE SETTINGS
NOTE: OTHER END USERS INCLUDE COSMETIC CLINICS, DIAGNOSTIC LABORATORIES, CLINICAL RESEARCH, ACADEMIC & RESEARCH INSTITUTIONS, AND HEALTHCARE PROVIDERS.
15
MIDDLE EAST & AFRICA INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION & VOLUME IN THOUSAND UNITS)
ASSESSING GROWTH PATTERNS, INDUSTRY FORCES, REGULATORY LANDSCAPE, AND MARKET POTENTIAL ACROSS KEY GEOGRAPHIES AND COUNTRIES
15.2
MIDDLE EAST & AFRICA VOLUME ANALYSIS- 2024–2031 (THOUSAND UNITS)
15.3
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
15.4.1
KINGDOM OF SAUDI ARABIA (KSA)
15.4.2
UNITED ARAB EMIRATES (UAE)
15.4.3
OTHER GCC COUNTRIES
15.6
REST OF MIDDLE EAST & AFRICA
NOTE: REST OF GCC INCLUDES BAHRAIN AND OMAN.
NOTE: REST OF MIDDLE EAST INCLUDES ISRAEL, IRAN, IRAQ, JORDAN, YEMEN AND OTHER COUNTRIES.
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
16.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
16.3
REVENUE SHARE ANALYSIS
16.4
MARKET SHARE ANALYSIS
16.5
BRAND COMPARISON (SYRINGES)
16.5.1
BD (BD NEOPAK XTRAFLOW)
16.5.2
TERUMO CORPORATION (PLAJEX PRE-FILLABLE SYRINGES)
16.5.3
CARDINAL HEALTH (MONOJECT)
16.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
16.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
16.6.5.1
COMPANY FOOTPRINT
16.6.5.2
REGION FOOTPRINT
16.6.5.3
PRODUCT FOOTPRINT
16.6.5.4
FORMULATION PACKAGING FOOTPRINT
16.6.5.5
THERAPEUTIC APPLICATION FOOTPRINT
16.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
16.7.1
PROGRESSIVE COMPANIES
16.7.2
RESPONSIVE COMPANIES
16.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
16.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
16.7.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
16.8
COMPANY VALUATION AND FINANCIAL METRICS
16.9
COMPETITIVE SCENARIO
16.9.4
OTHER DEVELOPMENTS
IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE MEA INJECTABLE DRUG DELIVERY MARKET LANDSCAPE
17.1
INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (KEY PLAYERS)
17.1.3
TERUMO CORPORATION
17.1.7
WEST PHARMACEUTICAL SERVICES
17.2
INJECTABLE DRUG DELIVERY DEVICE MANUFACTURERS (OTHER PLAYERS)
17.3
INJETCABLE DRUG DELIVERY FORMULATION MANUFACTURERS
17.2.5
HIKMA PHARMACEUTICALS PLC
17.2.7
F. HOFFMANN-LA ROCHE LTD
17.2.8
ELI LILLY AND COMPANY
17.4
INJECTABLE DRUG DELIVERY FORMULATION MANUFACTURERS (OTHER PLAYERS)
18.1.1.1
KEY DATA FROM SECONDARY SOURCES
18.1.2.1
KEY DATA FROM PRIMARY SOURCES
18.1.2.2
KEY PRIMARY PARTICIPANTS
18.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
18.1.2.4
KEY INDUSTRY INSIGHTS
18.2
MARKET SIZE ESTIMATION
18.2.1
BOTTOM-UP APPROACH
18.2.3
BASE NUMBER CALCULATION
18.3
MARKET FORECAST APPROACH
18.6
RESEARCH ASSUMPTIONS
18.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
19.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
19.3
CUSTOMIZATION OPTIONS
19.3.2
COMPANY INFORMATION
19.3.3
GEOGRAPHIC ANALYSIS
19.3.4
REGIONAL/COUNTRY LEVEL MARKET SHARE ANALYSIS
19.3.5
COUNTRY LEVEL VOLUME ANALYSIS
19.3.6
BY PRODUCT MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
19.3.7
ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS
*CONTENTS IN THE TOC/ MARKET SEGMENTS ARE TENTATIVE AND MIGHT CHANGE AS THE RESEARCH PROCEEDS.
*LIST OF COMPANIES IS NOT EXHAUSTIVE AND MIGHT CHANGE DURING THE COURSE OF STUDY
Growth opportunities and latent adjacency in Middle East & Africa Injectable Drug Delivery Market